Finding a druggable target for schizophrenia.
Instituto de Neurociencias, Consejo Superior de Investigaciones Científicas and Universidad Miguel Hernández, 03550 Sant Joan d´Alacant, Alicante, Spain. brico@umh.es
Beatriz
B
Rico
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D058534:Class I Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D020890:Neuregulin-1 / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines / Q000494:pharmacology*; D066247:Receptor, ErbB-4; D012559:Schizophrenia / Q000235:genetics* / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*
C477872:IC 87114; C094131:NRG1 protein, human; D020890:Neuregulin-1; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human; C587689:ERBB4 protein, human; D066246:ErbB Receptors; D066247:Receptor, ErbB-4; D000225:Adenine